Treatment for relapsed acute myeloid leukemia: What is new?

Current Opinion in Hematology

Volumn 19, Issue 2, 2012, Pages 89-94

  Ofran, Yishai ^a,b   Rowe, Jacob M ^a,b  

^a RAMBAM MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

allogeneic transplantation; complete remission 2; intensive chemotherapy; minimal residual disease; relapsed refractory acute myeloid leukemia

Indexed keywords

AEG 35156; AMSACRINE; ANTHRACYCLINE; AZACITIDINE; CLADRIBINE; CLOFARABINE; CYTARABINE; DAUNORUBICIN; DENDRITIC CELL VACCINE; EVEROLIMUS; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; LENALIDOMIDE; LESTAURTINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PURINE NUCLEOSIDE; QUIZARTINIB; RAPAMYCIN; RIDAFOROLIMUS; SORAFENIB; X LINKED INHIBITOR OF APOPTOSIS;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADD ON THERAPY; ALLOGENEIC STEM CELL TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL PROTOCOL; CYTOGENETICS; DRUG MEGADOSE; DRUG TARGETING; GENE MUTATION; HLA MATCHING; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; ENZYME INHIBITORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; RISK ASSESSMENT; TRANSPLANTATION CONDITIONING;

EID: 84857038882     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32834ff4e1     Document Type: Review

References (54)

1. Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005; 23:1969-1978. (Pubitemid 46211376)
2. Rowe JM, Li X, Cassileth PA, et al. Very poor survival of patients with AML who relapse after achieving a first complete remission: The Eastern Cooperative Oncology Group Experience. Blood 2005; 106:546a.
3. Thomas ML. Palliative care and induction therapy: A complimentary approach to the treatment of acute myeloid leukemia. Leuk Res 2001; 25:681-684. (Pubitemid 32492945)
4. Kurosawa S, Yamaguchi T, Miyawaki S, et al. Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse. Haematologica 2010; 95:1857-1864. The largest retrospective study of prognosis after first relapse. 5. Chevallier P, Labopin M, Turlure P, et al. A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: A GOELAMS study. Leukemia 2011; 25:939-944. The scoring scale derived from retrospective analysis of GOELAM study results.
5. Giles F, Verstovsek S, Garcia-Manero G, et al. Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. Br J Haematol 2006; 134:58-60.
6. Ofran Y, Rowe JM. Induction and postremission strategies in acute myeloid leukemia: What is new? Curr Opin Hematol 2011; 18:83-88.
7. Juliusson G. Most 70-to 79-year-old patients with acute myeloid leukemia do benefit from intensive treatment. Blood 2011; 117:3473-3474.
8. Walter RB, Kantarjian HM, Huang X, et al. Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: A combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. J Clin Oncol 2010; 28:1766-1771. A retrospective observation emphasizing significant prognostic value of complete remission 1.
9. Rowe JM, Tallman MS. How I treat acute myeloid leukemia. Blood 2010; 116:3147-3156.
10. Ferrara F, Fazi P, Venditti A, et al. Heterogeneity in the therapeutic approach to relapsed elderly patients with acute myeloid leukaemia: A survey from the Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) Acute Leukaemia Working Party. Hematol Oncol 2008; 26:104-107. (Pubitemid 351951339)
11. Litzow MR, Othus M, Cripe LD, et al. Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: A report from the Eastern Cooperative Oncology Group. Br J Haematol 2010; 148:217-225. Prospective comparison between three different cytarabine-based induction protocols.
12. Estey EH. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia 2000; 14:476-479. (Pubitemid 30142875)
13. Keating MJ, Kantarjian H, Smith TL, et al. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 1989; 7:1071-1080. (Pubitemid 19196530)
14. Rowe JM, Mazza JJ, Hines JD, et al. Mitoxantrone and etoposide in patients with relapsed and refractory acute nonlymphocytic leukemia. Haematol Blood Transfus 1990; 33:326-329.
15. Kolb HJ, Simoes B, Schmid C. Stem cell transplants for patients with relapsed/refractory leukaemia. Curr Opin Hematol 2009; 16:444-452.
16. Duval M, Klein JP, He W, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 2010; 28:3730-3738. Large retrospective series from the Center for International Blood and Marrow Transplant Research
17. Schmid C, Schleuning M, Schwerdtfeger R, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006; 108:1092-1099. (Pubitemid 44154650)
18. Tsitsikas DA, Warcel-Sibony D, Oakervee HE, et al. A phase II trial of sequential treatment with cytoreductive therapy and reduced intensity conditioning allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukaemia, high-risk MDS and other high risk myeoid malignancies: An interim report. Blood 2010; 116:3480a.
19. Ulrich D, Hans M, Sabine M, et al. Long-term results of a fast transplant versus a classical conditioning strategy for allogeneic stem cell transplantation of high risk acute myeloid leukemia (AML) patients. Blood 2010; 116:1336a.
20. Gergis U, Ritchie E, Roboz GJ, et al. A novel sequential treatment utilizing CPX-351 as salvage chemotherapy followed by a reduced intensity conditioning allogeneic stem-cell transplantation for patients with refractory leukemia. Blood 2010; 116:1334.
21. Ruggeri A, Ciceri F, Gluckman E, et al. Alternative donors hematopoietic stem cells transplantation for adults with acute myeloid leukemia: Umbilical cord blood or haploidentical donors? Best Pract Res Clin Haematol 2010; 23:207-216. A review discussing various aspects in choosing the best donor for allogeneic transplantation.
22. Sierra J, Martino R, Sanchez B, et al. Hematopoietic transplantation from adult unrelated donors as treatment for acute myeloid leukemia. Bone Marrow Transplant 2008; 41:425-437. (Pubitemid 351395096)
23. Linker CA, Owzar K, Powell B, et al. Auto-SCT for AML in second remission: CALGB study 9620. Bone Marrow Transplant 2009; 44:353-359.
24. Litzow MR. Progress and strategies for patients with relapsed and refractory acute myeloid leukemia. Curr Opin Hematol 2007; 14:130-137. (Pubitemid 46175097)
25. Burnett AK, Russell NH, Kell J, et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 2010; 28:2389-2395. Results of using clofarabine in older patients with relapsed AML.
26. Becker PS, Kantarjian HM, Appelbaum FR, et al. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Br J Haematol 2011; 155:182-189.
27. Faderl S, Gandhi V, Kantarjian HM. Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia. Curr Opin Hematol 2008; 15:101-107. (Pubitemid 351323149)
28. Levis M, Ravandi F, Wang ES, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 2011; 117:3294-3301.
29. Sharma M, Ravandi F, Bayraktar UD, et al. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biol Blood Marrow Transplant 2011; 17:1874-1877.
30. Cortes J, Perl A, Smith C, et al. A phase II open-label, AC220 monotherapy efficacy (ACE) study in patients with acute myeloid leukemia (AML) with FLT3-ITD activating mutations: Interim results. Haematologica 2011; 96:1019a.
31. Lamba JK, Crews KR, Pounds SB, et al. Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes. Pharmacogenomics 2011; 12:327-339.
32. Boehm A, Mayerhofer M, Herndlhofer S, et al. Evaluation of in vivo antineoplastic effects of rapamycin in patients with chemotherapy-refractory AML. Eur J Intern Med 2009; 20:775-778.
33. Rizzieri DA, Feldman E, Dipersio JF, et al. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2008; 14:2756-2762.
34. Wei AH, Sadawarte S, Catalano J, et al. A phase Ib study combining the mTOR inhibitor everolimus (RAD001) with low-dose cytarabine in untreated elderly AML. Blood 2010; 116:3299a.
35. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28:562-569. A prospective randomized study of azacitidine in elderly patients.
36. Czibere A, Bruns I, Kroger N, et al. 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: A retrospective analysis. Bone Marrow Transplant 2010; 45:872-876.
37. Platzbecker U, Wermke M, Radke J, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: Results of the RELAZA trial. Leukemia 2011; doi:10.1038/leu.2011.234. [Epub ahead of print]
38. Blum W, Klisovic RB, Becker H, et al. Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol 2010; 28:4919-4925.
39. Schimmer AD, Estey EH, Borthakur G, et al. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol 2009; 27:4741-4746.
40. Barrett AJ, Le Blanc K. Immunotherapy prospects for acute myeloid leukaemia. Clin Exp Immunol 2010; 161:223-232.
41. Van Tendeloo VF, Van de Velde A, Van Driessche A, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A 2010; 107:13824-13829. A proof of concept study demonstrating that remission can be induced by dendritic cell vaccine. 43.
42. Warren EH, Fujii N, Akatsuka Y, et al. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood 2010; 115:3869-3878. Description of a therapeutic potential of adoptive T-cell transfer targeting recipient's minor antigen and its side effect in a small series of patients
43. Guo M, Hu KX, Yu CL, et al. Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients. Blood 2011; 117:936-941. A novel approach to improving induction protocol based on immunomodulation with an exact mechanism to be clarified.
44. Cassileth PA, Harrington DP, Hines JD, et al. Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. J Clin Oncol 1988; 6:583-587.
45. Hiddemann W, Martin WR, Sauerland CM, et al. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: A proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy. Leukemia 1990; 4:184-188. (Pubitemid 20099890)
46. Ganzel C, Rowe JM. Prognostic factors in adult acute leukemia. Hematol Oncol Clin North Am 2011; 25:1163-1187.
47. Lacombe F, Arnoulet C, Maynadie M, et al. Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: A GOELAMS study. Leukemia 2009; 23:350-357.
48. Elliott MA, Litzow MR, Letendre LL, et al. Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. Blood 2007; 110:4172-4174. (Pubitemid 351377779)
49. Kern W, Haferlach T, Schoch C, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: Data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 2003; 101:64-70. (Pubitemid 36025888)
50. Rowe JM, Kim HT, Cassileth PA, et al. Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: A report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group. Cancer 2010; 116:5012-5021. A retrospective study of large-scale Eastern Cooperative Oncology Group data demonstrating the value of early (day 14) reinduction.
51. Stone RM. Should the presence of minimal residual disease (MRD) and morphologic complete remission alter postremission strategy in AML? Best Pract Res Clin Haematol 2011; 24:509-514. Important discussion of an appropriate incorporation of MRD monitoring into follow-up standards.
52. Perez-Garcia A, Brunet S, Berlanga JJ, et al. CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy. Leukemia 2009; 23:486-491. An impressive observation demonstrating the importance of endogenous immune system activity in maintaining remission.
53. Walter RB, Appelbaum FR, Tallman MS, et al. Shortcomings in the clinical evaluation of new drugs: Acute myeloid leukemia as paradigm. Blood 2010; 116:2420-2428.
54. Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011; 25:1147-1152. First available data regarding personalized selection of effective therapeutic agents according to specific mutations.